A Phase 1 Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ACE-232 in Patients with Metastatic Castration-Resistant Prostate Cancer (CRPC)

Status: Recruiting

Eligibility Criteria

Sex: Male
Age Group: 18 years and over
This study is NOT accepting healthy volunteers

Inclusion Criteria:

- diagnosis of Metastatic Castration-resistant Prostate Cancer (MCRPC) with

•ongoing androgen deprivation therapy (ADT) or had bilateral orchiectomy - difficult to treat or intolerant to standard treatment - may be restricted in physically strenuous activity but able to walk and carry out work of a light or sedentary nature, e.g., light house work, office work - see link to clinicaltrials.gov for complete inclusion criteria

Exclusion Criteria:

- spinal cord compression or known brain metastases - severe cardiovascular disorders - known gastrointestinal (GI) disorder or GI procedure - poorly controlled diabetes - active or uncontrolled autoimmune disease - see link to clinicaltrials.gov for complete exclusion criteria

Conditions & Interventions

Conditions:
Cancer
Keywords:
Clinics and Surgery Center (CSC), MCRPC, Metastatic Castration-resistant Prostate Cancer, Prostate Cancer

More Information

Description: The purpose of this research is to collect information about the safety and tolerability of the study drug ACE-232, along with how well it works to control metastatic castration-resistant prostate cancer (mCRPC).
Study Contact: Emmanuel Antonarakis - anton401@umn.edu
Principal Investigator: Emmanuel Antonarakis
Phase: PHASE1
IRB Number: STUDY00024643